ImmunOs has developed a new class of biologics for the treatment of cancer and autoimmune disease. The Company´s product candidates are single molecules, which are based on naturally occurring human HLA-proteins and simultaneously target multiple receptors of the innate immune system. ImmunOs Therapeutics’ lead compound activates anti-tumor responses by blocking several specific LILRB (leukocyte immunoglobulin-like) immune receptors.
The Company has established a comprehensive data set of validated results with a global team of scientific and commercial immunotherapy, immunology, and oncology experts. These human HLA-proteins can be used for the treatment of cancer and other serious diseases. In preclinical studies, therapeutic efficacy has been demonstrated as monotherapy and in combination with standard-of-care cancer therapies.
ImmunOs Therapeutics’ mission is to develop the next generation of novel immunotherapeutics that will improve the lives of patients with serious diseases.
ImmunOs Therapeutics is building a growing pipeline of novel drug candidates to a) antagonize multiple types of solid and liquid tumors, and b) treat diverse diseases (e.g. autoimmune disease) through the modulation of the immune system.